Merck ramps up Alzheimer's efforts with $520m Bionomics deal
This article was originally published in Scrip
Executive Summary
Merck & Co and Bionomics have struck their second major deal in a year to collaborate on BNC375, Bionomics' Alzheimer's disease candidate.